克林霉素降低资源匮乏地区早产风险:随机安慰剂对照临床试验
在印度南部农村开展随机双盲安慰剂对照试验,纳入孕13+0/7至20+6/7周、阴道pH≥5.0的单胎孕妇1727例,随机接受口服克林霉素300 mg每日两次共5天或安慰剂。克林霉素组与安慰剂组37周前早产率无显著差异。
要点
- 阴道pH≥5.0的单胎孕妇口服克林霉素300 mg每日两次共5天,未降低37周前早产率。
- 克林霉素组37周前早产115/826(13.9%)vs 安慰剂组111/806(13.8%),组间差0.2%(95%CI -3.2至3.5%,P=0.93)。
- 34周前早产、低出生体重、流产、死产及新生儿死亡发生率两组均无差异。
核心结论
- 在这一环境中,口服克林霉素未降低阴道pH≥5.0孕妇的早产率。
研究设计与样本
- 随机双盲安慰剂对照临床试验,在印度卡纳塔克邦于2013年10月至2015年7月产前检查时招募孕13+0/7至20+6/7周、阴道pH≥5.0的单胎孕妇。
- 共筛查6476例,随机1727例(区组随机,每组6例;克林霉素组n=866,安慰剂组n=861)。
- 干预为口服克林霉素300 mg每日两次共5天或外观相同的安慰剂。
主要发现
- 37周前早产率:克林霉素组115/826(13.9%)vs 安慰剂组111/806(13.8%),组间差0.2%(95%CI -3.2至3.5%,P=0.93)。
- 34周前早产率:克林霉素组40/826(4.8%)vs 安慰剂组37/806(4.6%),组间差0.3%(95%CI -1.8至2.3%,P=0.81)。
- 出生体重<2500 g、<1500 g、流产、死产或新生儿死亡的发生率两组均未检出差异。
- 服药依从性高,超过94%的胶囊被服用。
临床怎么用
- 作者结论为在这一环境中口服克林霉素未降低阴道pH≥5.0孕妇的早产率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether oral clindamycin reduces the risk of preterm birth (PTB) in women with abnormal vaginal microflora as evidenced by a vaginal pH ≥5.0. DESIGN: Randomised double-blind placebo-controlled trial. SETTING: Rural southern India. POPULATION: Pregnant women with a singleton fetus between 13+0/7 weeks and 20+6/7 weeks. METHODS: Pregnant women were recruited during prenatal visits in Karnataka, India, from October 2013 to July 2015. Women were required to have a singleton fetus between 13+0/7 weeks and 20+6/7 weeks and an elevated vaginal pH (≥5.0) by colorimetric assessment. Participants were randomised to either oral clindamycin 300 mg twice daily for 5 days or an identical-appearing placebo. MAIN OUTCOME MEASURES: The primary outcome was the incidence of PTB, defined as delivery before 37+0/7 weeks. RESULTS: Of the 6476 screened women, 1727 women were randomised (block randomised in groups of six; clindamycin n = 866, placebo n = 861). The demographic, reproductive, and anthropomorphometric characteristics of the study groups were similar. Compliance was high, with over 94% of capsules being taken. The rate of PTB before 37 weeks was comparable between the two groups [clindamycin 115/826 (13.9%) versus placebo 111/806 (13.8%), between-group difference 0.2% (95% CI -3.2 to 3.5%, P = 0.93)], as was PTB at less than 34 weeks [clindamycin 40/826 (4.8%) versus placebo group 37/806 (4.6%), between-group difference 0.3% (95% CI -1.8 to 2.3%, P = 0.81)]. No differences were detected in the incidence of birthweight of<2500 g, <1500 g, miscarriage, stillbirth or neonatal death. CONCLUSION: In this setting, oral clindamycin did not decrease PTB among women with vaginal pH ≥5.0. TWEETABLE ABSTRACT: Oral clindamycin between 13+0/7 and 20+6/7 weeks does not prevent preterm birth in women with a vaginal pH ≥5.0.
引用
- Bellad MB, Hoffman MK, Mallapur AA, et al. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial. BJOG. 2018. PMID: 29790266. doi:10.1111/1471-0528.15290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。